Titre : Furanes

Furanes : Questions médicales fréquentes

Termes MeSH sélectionnés :

Pilot Projects
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Furanes : Questions médicales les plus fréquentes", "headline": "Furanes : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Furanes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-26", "dateModified": "2025-04-21", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Furanes" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Composés hétéromonocycliques", "url": "https://questionsmedicales.fr/mesh/D006573", "about": { "@type": "MedicalCondition", "name": "Composés hétéromonocycliques", "code": { "@type": "MedicalCode", "code": "D006573", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "4-Butyrolactone", "alternateName": "4-Butyrolactone", "url": "https://questionsmedicales.fr/mesh/D015107", "about": { "@type": "MedicalCondition", "name": "4-Butyrolactone", "code": { "@type": "MedicalCode", "code": "D015107", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.312.150" } } }, { "@type": "MedicalWebPage", "name": "Anhydrides citraconiques", "alternateName": "Citraconic Anhydrides", "url": "https://questionsmedicales.fr/mesh/D002949", "about": { "@type": "MedicalCondition", "name": "Anhydrides citraconiques", "code": { "@type": "MedicalCode", "code": "D002949", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.312.250" } } }, { "@type": "MedicalWebPage", "name": "Darunavir", "alternateName": "Darunavir", "url": "https://questionsmedicales.fr/mesh/D000069454", "about": { "@type": "MedicalCondition", "name": "Darunavir", "code": { "@type": "MedicalCode", "code": "D000069454", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.312.303" } } }, { "@type": "MedicalWebPage", "name": "Furfural", "alternateName": "Furaldehyde", "url": "https://questionsmedicales.fr/mesh/D005662", "about": { "@type": "MedicalCondition", "name": "Furfural", "code": { "@type": "MedicalCode", "code": "D005662", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.312.355" } } }, { "@type": "MedicalWebPage", "name": "Lasalocide", "alternateName": "Lasalocid", "url": "https://questionsmedicales.fr/mesh/D007832", "about": { "@type": "MedicalCondition", "name": "Lasalocide", "code": { "@type": "MedicalCode", "code": "D007832", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.312.490" } } }, { "@type": "MedicalWebPage", "name": "Anhydrides maléiques", "alternateName": "Maleic Anhydrides", "url": "https://questionsmedicales.fr/mesh/D008299", "about": { "@type": "MedicalCondition", "name": "Anhydrides maléiques", "code": { "@type": "MedicalCode", "code": "D008299", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.312.520" } } }, { "@type": "MedicalWebPage", "name": "Monensin", "alternateName": "Monensin", "url": "https://questionsmedicales.fr/mesh/D008985", "about": { "@type": "MedicalCondition", "name": "Monensin", "code": { "@type": "MedicalCode", "code": "D008985", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.312.600" } } }, { "@type": "MedicalWebPage", "name": "Naftidrofuryl", "alternateName": "Nafronyl", "url": "https://questionsmedicales.fr/mesh/D009257", "about": { "@type": "MedicalCondition", "name": "Naftidrofuryl", "code": { "@type": "MedicalCode", "code": "D009257", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.312.620" } } }, { "@type": "MedicalWebPage", "name": "Nitrofuranes", "alternateName": "Nitrofurans", "url": "https://questionsmedicales.fr/mesh/D009581", "about": { "@type": "MedicalCondition", "name": "Nitrofuranes", "code": { "@type": "MedicalCode", "code": "D009581", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.312.649" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "3-(2-(5-Nitro-2-furyl)vinyl)-1,2,4-oxadiazol-5-amine", "alternateName": "5-Amino-3-((5-nitro-2-furyl)vinyl)-1,2,4-oxadiazole", "url": "https://questionsmedicales.fr/mesh/D013184", "about": { "@type": "MedicalCondition", "name": "3-(2-(5-Nitro-2-furyl)vinyl)-1,2,4-oxadiazol-5-amine", "code": { "@type": "MedicalCode", "code": "D013184", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.312.649.200" } } }, { "@type": "MedicalWebPage", "name": "N-(4-(5-Nitro-2-furyl)-1,3-thiazol-2-yl)formamide", "alternateName": "FANFT", "url": "https://questionsmedicales.fr/mesh/D005200", "about": { "@type": "MedicalCondition", "name": "N-(4-(5-Nitro-2-furyl)-1,3-thiazol-2-yl)formamide", "code": { "@type": "MedicalCode", "code": "D005200", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.312.649.290" } } }, { "@type": "MedicalWebPage", "name": "Furagine", "alternateName": "Furagin", "url": "https://questionsmedicales.fr/mesh/D005661", "about": { "@type": "MedicalCondition", "name": "Furagine", "code": { "@type": "MedicalCode", "code": "D005661", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.312.649.308" } } }, { "@type": "MedicalWebPage", "name": "Furazolidone", "alternateName": "Furazolidone", "url": "https://questionsmedicales.fr/mesh/D005664", "about": { "@type": "MedicalCondition", "name": "Furazolidone", "code": { "@type": "MedicalCode", "code": "D005664", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.312.649.313" } } }, { "@type": "MedicalWebPage", "name": "2-(Furan-2-yl)-3-(5-nitrofuran-2-yl)prop-2-énamide", "alternateName": "Furylfuramide", "url": "https://questionsmedicales.fr/mesh/D005668", "about": { "@type": "MedicalCondition", "name": "2-(Furan-2-yl)-3-(5-nitrofuran-2-yl)prop-2-énamide", "code": { "@type": "MedicalCode", "code": "D005668", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.312.649.330" } } }, { "@type": "MedicalWebPage", "name": "Nifuratel", "alternateName": "Nifuratel", "url": "https://questionsmedicales.fr/mesh/D009545", "about": { "@type": "MedicalCondition", "name": "Nifuratel", "code": { "@type": "MedicalCode", "code": "D009545", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.312.649.410" } } }, { "@type": "MedicalWebPage", "name": "Nitrofurantoïne", "alternateName": "Nitrofurantoin", "url": "https://questionsmedicales.fr/mesh/D009582", "about": { "@type": "MedicalCondition", "name": "Nitrofurantoïne", "code": { "@type": "MedicalCode", "code": "D009582", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.312.649.566" } } }, { "@type": "MedicalWebPage", "name": "Nitrofural", "alternateName": "Nitrofurazone", "url": "https://questionsmedicales.fr/mesh/D009583", "about": { "@type": "MedicalCondition", "name": "Nitrofural", "code": { "@type": "MedicalCode", "code": "D009583", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.312.649.691" } } }, { "@type": "MedicalWebPage", "name": "Nitrovin", "alternateName": "Nitrovin", "url": "https://questionsmedicales.fr/mesh/D009610", "about": { "@type": "MedicalCondition", "name": "Nitrovin", "code": { "@type": "MedicalCode", "code": "D009610", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.312.649.750" } } } ] }, { "@type": "MedicalWebPage", "name": "Ranitidine", "alternateName": "Ranitidine", "url": "https://questionsmedicales.fr/mesh/D011899", "about": { "@type": "MedicalCondition", "name": "Ranitidine", "code": { "@type": "MedicalCode", "code": "D011899", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.312.750" } } } ], "about": { "@type": "MedicalCondition", "name": "Furanes", "alternateName": "Furans", "code": { "@type": "MedicalCode", "code": "D005663", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Anja Rahn", "url": "https://questionsmedicales.fr/author/Anja%20Rahn", "affiliation": { "@type": "Organization", "name": "Zurich University of Applied Sciences, Institute of Chemistry and Biotechnology, Coffee Excellence Center & Analytical Technologies, Wädenswil, Switzerland. Electronic address: rahj@zhaw.ch." } }, { "@type": "Person", "name": "Chahan Yeretzian", "url": "https://questionsmedicales.fr/author/Chahan%20Yeretzian", "affiliation": { "@type": "Organization", "name": "Zurich University of Applied Sciences, Institute of Chemistry and Biotechnology, Coffee Excellence Center & Analytical Technologies, Wädenswil, Switzerland. Electronic address: yere@zhaw.ch." } }, { "@type": "Person", "name": "Yinbo Wan", "url": "https://questionsmedicales.fr/author/Yinbo%20Wan", "affiliation": { "@type": "Organization", "name": "Key Laboratory of Chemical Biology and Traditional Chinese Medicine Research (Ministry of Education of China), Hunan Normal University, Changsha 410081, China." } }, { "@type": "Person", "name": "Haiyun Peng", "url": "https://questionsmedicales.fr/author/Haiyun%20Peng", "affiliation": { "@type": "Organization", "name": "Key Laboratory of Chemical Biology and Traditional Chinese Medicine Research (Ministry of Education of China), Hunan Normal University, Changsha 410081, China." } }, { "@type": "Person", "name": "Guisheng Deng", "url": "https://questionsmedicales.fr/author/Guisheng%20Deng", "affiliation": { "@type": "Organization", "name": "Key Laboratory of Chemical Biology and Traditional Chinese Medicine Research (Ministry of Education of China), Hunan Normal University, Changsha 410081, China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Changes in Cerebrovascular Procedures and Outcomes During COVID-19 Using the National Surgery Quality Improvement Project.", "datePublished": "2023-06-27", "url": "https://questionsmedicales.fr/article/37385438", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.wneu.2023.06.094" } }, { "@type": "ScholarlyArticle", "name": "Integrated science, technology, engineering, and mathematics project-based learning for physics learning from neuroscience perspectives.", "datePublished": "2023-06-19", "url": "https://questionsmedicales.fr/article/37404578", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpsyg.2023.1136246" } }, { "@type": "ScholarlyArticle", "name": "Ablation of Projection Glutamatergic Neurons in the Lateral Cerebellar Nuclei Alters Motor Coordination in Vglut2-Cre+ Mice.", "datePublished": "2023-06-08", "url": "https://questionsmedicales.fr/article/37289359", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12311-023-01575-9" } }, { "@type": "ScholarlyArticle", "name": "Future climate projections using the LARS-WG6 downscaling model over Upper Indus Basin, Pakistan.", "datePublished": "2023-06-07", "url": "https://questionsmedicales.fr/article/37284969", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10661-023-11419-y" } }, { "@type": "ScholarlyArticle", "name": "Interaction matters: Bottom-up driver interdependencies alter the projected response of phytoplankton communities to climate change.", "datePublished": "2023-06-02", "url": "https://questionsmedicales.fr/article/37265254", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/gcb.16799" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétéromonocycliques", "item": "https://questionsmedicales.fr/mesh/D006573" }, { "@type": "ListItem", "position": 4, "name": "Furanes", "item": "https://questionsmedicales.fr/mesh/D005663" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Furanes - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Furanes", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-05", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Furanes", "description": "Comment diagnostiquer une exposition aux furanes ?\nQuels tests sont utilisés pour détecter les furanes ?\nQuels symptômes indiquent une intoxication aux furanes ?\nY a-t-il des marqueurs biologiques pour les furanes ?\nComment évaluer le risque d'exposition aux furanes ?", "url": "https://questionsmedicales.fr/mesh/D005663?mesh_terms=Pilot+Projects&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Furanes", "description": "Quels sont les symptômes d'une intoxication aiguë aux furanes ?\nLes furanes provoquent-ils des effets à long terme ?\nComment les furanes affectent-ils le système respiratoire ?\nY a-t-il des symptômes spécifiques chez les travailleurs exposés ?\nLes furanes affectent-ils le système immunitaire ?", "url": "https://questionsmedicales.fr/mesh/D005663?mesh_terms=Pilot+Projects&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Furanes", "description": "Comment prévenir l'exposition aux furanes ?\nQuelles mesures de sécurité doivent être mises en place ?\nLes furanes peuvent-ils être évités dans l'industrie alimentaire ?\nQuelles sont les réglementations concernant les furanes ?\nLes travailleurs doivent-ils être formés sur les furanes ?", "url": "https://questionsmedicales.fr/mesh/D005663?mesh_terms=Pilot+Projects&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Furanes", "description": "Quel est le traitement de l'intoxication aux furanes ?\nDes antidotes existent-ils pour les furanes ?\nComment traiter les irritations cutanées causées par les furanes ?\nLes soins d'urgence sont-ils nécessaires en cas d'exposition ?\nQuel suivi médical est recommandé après exposition ?", "url": "https://questionsmedicales.fr/mesh/D005663?mesh_terms=Pilot+Projects&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Furanes", "description": "Quelles complications peuvent survenir après exposition aux furanes ?\nLes furanes peuvent-ils causer des cancers ?\nComment les furanes affectent-ils la reproduction ?\nLes furanes peuvent-ils affecter le foie ?\nY a-t-il des effets sur le système nerveux ?", "url": "https://questionsmedicales.fr/mesh/D005663?mesh_terms=Pilot+Projects&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Furanes", "description": "Qui est le plus à risque d'exposition aux furanes ?\nLes fumeurs sont-ils plus à risque d'exposition ?\nLes enfants sont-ils plus vulnérables aux furanes ?\nQuels facteurs environnementaux augmentent le risque ?\nLes personnes ayant des antécédents médicaux sont-elles à risque ?", "url": "https://questionsmedicales.fr/mesh/D005663?mesh_terms=Pilot+Projects&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une exposition aux furanes ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'historique d'exposition et des tests biologiques pour détecter des métabolites." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour détecter les furanes ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des analyses de sang et d'urine peuvent être effectuées pour identifier les métabolites des furanes." } }, { "@type": "Question", "name": "Quels symptômes indiquent une intoxication aux furanes ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des nausées, des vomissements, des douleurs abdominales et des vertiges." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs biologiques pour les furanes ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des marqueurs comme le 2-furylméthylcétone peuvent être mesurés dans les fluides corporels." } }, { "@type": "Question", "name": "Comment évaluer le risque d'exposition aux furanes ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Une évaluation des conditions de travail et des sources potentielles d'exposition est nécessaire." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une intoxication aiguë aux furanes ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes aigus incluent des maux de tête, des nausées, des irritations cutanées et respiratoires." } }, { "@type": "Question", "name": "Les furanes provoquent-ils des effets à long terme ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une exposition prolongée peut entraîner des effets chroniques comme des troubles neurologiques." } }, { "@type": "Question", "name": "Comment les furanes affectent-ils le système respiratoire ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent provoquer des irritations des voies respiratoires, des toux et des difficultés respiratoires." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques chez les travailleurs exposés ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les travailleurs peuvent présenter des symptômes comme des vertiges, des maux de tête et des troubles de la concentration." } }, { "@type": "Question", "name": "Les furanes affectent-ils le système immunitaire ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Une exposition prolongée peut altérer la réponse immunitaire, augmentant le risque d'infections." } }, { "@type": "Question", "name": "Comment prévenir l'exposition aux furanes ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des équipements de protection individuelle et suivre les protocoles de sécurité au travail." } }, { "@type": "Question", "name": "Quelles mesures de sécurité doivent être mises en place ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des systèmes de ventilation adéquats et des formations sur les risques chimiques sont essentiels." } }, { "@type": "Question", "name": "Les furanes peuvent-ils être évités dans l'industrie alimentaire ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en contrôlant les températures de cuisson et en évitant les méthodes de cuisson à haute température." } }, { "@type": "Question", "name": "Quelles sont les réglementations concernant les furanes ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des réglementations strictes existent pour limiter l'exposition professionnelle et environnementale." } }, { "@type": "Question", "name": "Les travailleurs doivent-ils être formés sur les furanes ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une formation sur les risques et les mesures de sécurité est cruciale pour les travailleurs." } }, { "@type": "Question", "name": "Quel est le traitement de l'intoxication aux furanes ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement consiste à retirer la source d'exposition et à gérer les symptômes cliniques." } }, { "@type": "Question", "name": "Des antidotes existent-ils pour les furanes ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas d'antidote spécifique, le traitement est symptomatique et de soutien." } }, { "@type": "Question", "name": "Comment traiter les irritations cutanées causées par les furanes ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Il est recommandé de rincer la zone affectée et d'appliquer des crèmes apaisantes ou corticostéroïdes." } }, { "@type": "Question", "name": "Les soins d'urgence sont-ils nécessaires en cas d'exposition ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en cas de symptômes graves, une évaluation médicale urgente est nécessaire." } }, { "@type": "Question", "name": "Quel suivi médical est recommandé après exposition ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi régulier est conseillé pour surveiller les effets à long terme et la santé générale." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir après exposition aux furanes ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des troubles respiratoires chroniques et des effets neurologiques." } }, { "@type": "Question", "name": "Les furanes peuvent-ils causer des cancers ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent un potentiel cancérigène, mais des recherches supplémentaires sont nécessaires." } }, { "@type": "Question", "name": "Comment les furanes affectent-ils la reproduction ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Une exposition peut entraîner des effets néfastes sur la reproduction et le développement fœtal." } }, { "@type": "Question", "name": "Les furanes peuvent-ils affecter le foie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une exposition peut entraîner des lésions hépatiques et des troubles fonctionnels du foie." } }, { "@type": "Question", "name": "Y a-t-il des effets sur le système nerveux ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Une exposition prolongée peut causer des troubles neurologiques, y compris des neuropathies." } }, { "@type": "Question", "name": "Qui est le plus à risque d'exposition aux furanes ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les travailleurs dans l'industrie chimique et alimentaire sont les plus exposés aux furanes." } }, { "@type": "Question", "name": "Les fumeurs sont-ils plus à risque d'exposition ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut augmenter l'exposition aux furanes présents dans la fumée de cigarette." } }, { "@type": "Question", "name": "Les enfants sont-ils plus vulnérables aux furanes ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les enfants peuvent être plus sensibles aux effets toxiques des furanes en raison de leur développement." } }, { "@type": "Question", "name": "Quels facteurs environnementaux augmentent le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "La pollution de l'air et la proximité d'industries émettrices de furanes augmentent le risque." } }, { "@type": "Question", "name": "Les personnes ayant des antécédents médicaux sont-elles à risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes avec des antécédents de maladies respiratoires ou hépatiques sont plus à risque." } } ] } ] }

Sources (10000 au total)

Changes in Cerebrovascular Procedures and Outcomes During COVID-19 Using the National Surgery Quality Improvement Project.

Explore the consequences of the coronavirus pandemic (COVID-19) on patients suffering from cerebrovascular disorders necessitating interventions.... Using the National Surgical Quality Improvement Program database, patients with cerebrovascular disease who underwent procedures before (2018-2019) and during (2020-2021) COVID-19 were identified. ICD... There was a significant rise in cerebrovascular accidents (CVAs) (9.96% vs. 12.28%) and a decrease in elective carotid endarterectomies (92.30% vs. 87.22%). Carotid stenting increased significantly (7... The pandemic led to more severe disease progression and reduced diagnoses due to screening delays, indicating deferred care. Prolonged operative times, extended hospital stays, and worsening outcomes,...

The Godmother Project: A Virtual Initiative to Support Pregnant and Postpartum Women in Brazil During the COVID-19 Pandemic.

The COVID-19 pandemic increased maternal distress and demand for social support and educational services, while restriction measures decreased the availability of these services.... The Godmother Project, a person-centered, WhatsApp-based support and health education initiative, was created after all in-person perinatal educational activities offered at 3 Brazilian hospitals were... The project provides direct communication between WhatsApp groups of 25-30 pregnant/postpartum women and a Godmother. It also offers access to a virtual library of educational materials prepared in re... Our findings suggest that WhatsApp groups of pregnant/postpartum women led by dedicated nurse educators can be an important tool to educate and support women during the perinatal period. This type of ...

The next phases of the Migrante Project: Study protocol to expand an observatory of migrant health on the Mexico-U.S. border.

Mexican migrants traveling across the Mexico-United States (U.S.) border region represent a large, highly mobile, and socially vulnerable subset of Mexican nationals. Population-level health data for ... In the next phases, two probability, face-to-face surveys of Mexican migrant flows will be conducted at key crossing points in Tijuana, Ciudad Juarez, and Matamoros (... Interview and biometric data from the Migrante project will help to characterize health care access and health status and identify variations in NCD-related outcomes, mental health, and substance use ...

Accelerated Epigenetic Aging Is Associated With Multiple Cardiometabolic, Hematologic, and Renal Abnormalities: A Project Baseline Health Substudy.

Epigenetic clocks estimate chronologic age using methylation levels at specific loci. We tested the hypothesis that accelerated epigenetic aging is associated with abnormal values in a range of clinic... The Project Baseline Health Study recruited 2502 participants, including 1661 with epigenetic age estimates from the Horvath pan-tissue clock. We classified individuals with extreme values as having e... The EAA (n=188) and epigenetic age deceleration (n=195) groups were identified as having EAA estimates ≥5 years or ≤-5 years, respectively. In primary analyses, individuals with EAA had higher values ... We report multiple cardiometabolic, hematologic, and physical function features characterizing individuals with EAA. These highlight factors that may mediate the adverse effects of aging and identify ... URL: https://www.... gov; Unique identifier: NCT03154346....

Palliative care teaching in the new internal medicine curriculum: Project ECHO-an innovative approach to postgraduate education.

The Internal Medicine Training (IMT) Programme is an evolution of Core Medical Training introduced in 2019. The IMT curriculum places an increased emphasis on palliative care; however, access to palli... The Project ECHO training programme involved multipoint video technology, telementoring, expert talks and case-based discussions over six sessions, and was fully mapped to the palliative care componen... By creating a community of practice, we provided virtual placements and over 9 hours of virtual direct contact with palliative medicine consultants; and in total, 921 individual attendances occurred, ... Project ECHO is an effective method of delivering teaching to trainees across a large geographical area. Course evaluation shows outstanding results in trainee satisfaction, confidence, knowledge, pat...